Apogenix GmbH (Apogenix)

Oncology Corporate Profile

Company Description

Apogenix develops protein therapeutics that could transform the treatment of life-threatening diseases by targeting critical pathways involved in the growth, migration, and apoptosis of diseased cells. The company's lead drug candidate APG101 is currently being evaluated in patients with glioblastoma ' a disease with a tremendous need for new and effective therapies.

Website: http://www.apogenix.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
Apoceptâ„¢ / APG101CD95 ligand inhibitorGlioblastoma Multiforme (GBM)II
Apoceptâ„¢ / APG101CD95 ligand inhibitorMyelodysplastic Syndrome (MDS)I
Apoceptâ„¢ / APG101CD95 ligand inhibitorVarious cancer typesI

View additional information on product candidates here »

Source: http://www.apogenix.com

Recent News Headlines

There are no news items to display